SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical : ABMD - Replacement Heart System
ABMD 184.23-1.3%2:16 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tech101 who wrote (145)11/1/2019 4:49:57 PM
From: tech101   of 147
 
Why Abiomed Stock Is Jumping TodayInvestors liked the medical device maker's Q2 results.



Keith Speights
(TMFFishBiz)

Oct 31, 2019 at 11:43AM

Author Bio

What happenedShares of Abiomed ( NASDAQ:ABMD) had jumped 11.9% higher as of 11:30 a.m. EDT on Thursday. The heart pump maker announced its fiscal 2019 second-quarter results before the market opened.

Abiomed reported Q2 revenue of $205 million, up 13% year over year. It posted earnings of $13.1 million, or $0.28 per share, down from the prior-year period net income of $50.1 million or $1.09 per share. The consensus Wall Street estimate was that the company would announce Q2 revenue of $206.5 million and earnings per share of $0.93.

IMAGE SOURCE: GETTY IMAGES.

So whatYou might wonder why Abiomed's shares would move higher when the company missed analysts' estimates for both the top and bottom lines. The answer boils down to why Abiomed missed the estimates.

The company's earnings were weighed down by an unrealized loss of $34.5 million, or $0.75 per share, related to its investment in Shockwave Medical. Without this negative impact, Abiomed would have handily beaten Wall Street's Q2 earnings expectations. This would-be earnings beat trumped any concerns about the company's narrow revenue miss.

Investors were also probably encouraged because Abiomed stuck by its previous full-year 2019 guidance. The company still anticipates total revenue will be between $885 million and $925 million, which reflects year-over-year growth between 15% and 20%.

Now whatThe fortunes of healthcare stocks like Abiomed hinge more on their future growth than on how a single quarter goes. Abiomed's future appears to be bright. Investors will especially want to monitor the company's launch of its Impella 5.5 with SmartAssist heart pump. Abiomed received premarket approval from the U.S. Food and Drug Administration for the device on Sept. 25, and it should boost Abiomed's sales.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext